The earnings call presented a strong set of highlights with significant clinical trial progress, patent extension, and financial fortification, although it was balanced by increased losses and expenses.

Company Guidance

During the Celcuity Second Quarter 2025 Financial Results Webcast and Conference Call, the company provided extensive guidance on their progress and future directions. Key highlights included the positive top-line data from the Phase III VIKTORIA-1 clinical trial for patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, where the gedatolisib triplet and doublet showed unprecedented improvements in progression-free survival (PFS) with hazard ratios of 0.24 and 0.33, respectively. The company also dosed the first patient in the VIKTORIA-2 trial, aiming to evaluate gedatolisib as a first-line treatment. Financially, Celcuity reported a second-quarter 2025 net loss of $45.3 million and ended the quarter with $168.4 million in cash, with pro forma cash totaling approximately $455 million post-financing activities. The company is gearing up for a potential FDA approval and market launch of gedatolisib, estimating an addressable market of $5 billion and projecting sufficient resources to fund operations through 2027.

Significant Milestones Achieved

Celcuity reported positive top line data from the PIK3CA wild-type cohort of the Phase III VIKTORIA-1 clinical trial, showing significant improvements in progression-free survival (PFS) for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer patients. Median PFS for the gedatolisib triplet was 9.3 months with a hazard ratio of 0.24, and 7.4 months for the gedatolisib doublet with a hazard ratio of 0.33.

Phase III VIKTORIA-2 Clinical Trial Progress

The first patient was dosed in the Phase III VIKTORIA-2 trial, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR-positive, HER2-negative advanced breast cancer.

Favorable Preliminary Results from Early-Phase Trials

Preliminary top line results from trials evaluating gedatolisib with darolutamide in prostate cancer and with trastuzumab biosimilar in HER2-positive breast cancer were favorable. The prostate cancer trial showed a 66% 6-month radiographic PFS rate.

Patent Extension for Gedatolisib

Celcuity extended patent exclusivity for gedatolisib into 2042 with a new dosing regimen patent.

Strong Financial Position

Celcuity raised approximately $287 million through public offerings, bringing cash, cash equivalents, and investments to $455 million on a pro forma basis, ensuring funding through 2027.

Celcuity (CELC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CELC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-1.02 / -	-0.7	―	―	―
Aug 14, 2025	2025 (Q2)	-0.88 / -1.04	-0.62	-67.74% (-0.42)	―
May 14, 2025	2025 (Q1)	- / -0.86	-0.64	-34.37% (-0.22)	―
Mar 31, 2025	2024 (Q4)	-0.86 / -0.86	-0.64	-34.37% (-0.22)	―
Nov 14, 2024	2024 (Q3)	-0.65 / -0.70	-0.83	15.66% (+0.13)	―
Aug 14, 2024	2024 (Q2)	-0.68 / -0.62	-0.66	6.06% (+0.04)	―
May 15, 2024	2024 (Q1)	-0.70 / -0.64	-0.55	-16.36% (-0.09)	―
Mar 27, 2024	2023 (Q4)	-0.73 / -0.65	-0.69	5.80% (+0.04)	―
Nov 13, 2023	2023 (Q3)	-0.68 / -0.83	-0.63	-31.75% (-0.20)	―
Aug 10, 2023	2023 (Q2)	-0.60 / -0.66	-0.55	-20.00% (-0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CELC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$51.89	$51.79	-0.19%
May 14, 2025	$10.86	$10.52	-3.13%
Mar 31, 2025	$10.11	$9.29	-8.11%
Nov 14, 2024	$14.11	$12.66	-10.28%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Celcuity (CELC) report earnings?

Celcuity (CELC) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Celcuity (CELC) earnings time?

Celcuity (CELC) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CELC EPS forecast?

CELC EPS forecast for the fiscal quarter 2025 (Q3) is -1.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing